Abstract：
To investigate the clinical efficacy of Fufang Huangqi decoction in combination with pyridostigmine bromide tablets, prednisone, and tacrolimus in the treatment of type I and II myasthenia gravis (MG) through changes in the clinical symptom scores of 100 patients with type I and II MG. This study also aimed to examine dose reductions and dis-continuation of these 3 Western medicines after administration of Fufang Huangqi decoction.
The clinical data on 100 patients with type I or II MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China, between June 2017 and June 2020 were collected. The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets, prednisone, and/or tacrolimus at the time of their hospital visit: the Fufang Huangqi decoction group (group A), the pyridostigmine bromide tablets + Fufang Huangqi decoction group (group B), the pyridostigmine bromide tablets + prednisone + Fufang Huangqi decoction group (group C), and the pyridostigmine bromide tablets + tacrolimus + Fufang Huangqi decoction group (group D). The average treatment time was (15.6 ± 11.5) months (range: 0.5-55 months). Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed.
An overall effectiveness rate of 86.00% was achieved in the 100 patients after treatment for (15.6 ± 11.5) months (range 0.5-55 months). The effectiveness rates were 85.71% in group A, 88.24% in group B, 76.92% in group C, and 80.00% in group D. The dosage of pyridostigmine bromide was reduced for 69.12% of the patients in group B for the first time after (4.2 ± 4.1) months, and 45.59% of the patients in group B discontinued pyridostigmine bromide after (8.8 ± 6.1) months. The dosage of pyridostigmine bromide was reduced for 46.15% of the patients in group C for the first time after (5.3 ± 3.4) months, and 23.08% of the patients in group C discontinued pyridostigmine bromide after (19.8 ± 11.0) months; 76.92% reduced hormone dosage after (2.8 ± 1.9) months, and 23.08% discontinued hormone treatment after (6.7 ± 2.9) months. The dosage of pyridostigmine bromide was reduced for 1 patient in group D after 1 month; this patient discontinued pyridostigmine bromide after 3 months and reduced tacrolimus dosage after 5 months. One patient in group D discontinued pyridostigmine bromide and tacrolimus on his own initiative at 0.5 months and took Fufang Huangqi decoction for 2 months without discontinuing Western medicine.
Fufang Huangqi decoction is effective for the treatment of type I and II MG and improves the associated clinical symptoms. Moreover, this agent is conducive to dose reductions and discontinuation of basic Western medicines, thereby reducing the side effects experienced by patients.
The clinical data on 100 patients with type I or II MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China, between June 2017 and June 2020 were collected. The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets, prednisone, and/or tacrolimus at the time of their hospital visit: the Fufang Huangqi decoction group (group A), the pyridostigmine bromide tablets + Fufang Huangqi decoction group (group B), the pyridostigmine bromide tablets + prednisone + Fufang Huangqi decoction group (group C), and the pyridostigmine bromide tablets + tacrolimus + Fufang Huangqi decoction group (group D). The average treatment time was (15.6 ± 11.5) months (range: 0.5-55 months). Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed.
An overall effectiveness rate of 86.00% was achieved in the 100 patients after treatment for (15.6 ± 11.5) months (range 0.5-55 months). The effectiveness rates were 85.71% in group A, 88.24% in group B, 76.92% in group C, and 80.00% in group D. The dosage of pyridostigmine bromide was reduced for 69.12% of the patients in group B for the first time after (4.2 ± 4.1) months, and 45.59% of the patients in group B discontinued pyridostigmine bromide after (8.8 ± 6.1) months. The dosage of pyridostigmine bromide was reduced for 46.15% of the patients in group C for the first time after (5.3 ± 3.4) months, and 23.08% of the patients in group C discontinued pyridostigmine bromide after (19.8 ± 11.0) months; 76.92% reduced hormone dosage after (2.8 ± 1.9) months, and 23.08% discontinued hormone treatment after (6.7 ± 2.9) months. The dosage of pyridostigmine bromide was reduced for 1 patient in group D after 1 month; this patient discontinued pyridostigmine bromide after 3 months and reduced tacrolimus dosage after 5 months. One patient in group D discontinued pyridostigmine bromide and tacrolimus on his own initiative at 0.5 months and took Fufang Huangqi decoction for 2 months without discontinuing Western medicine.
Fufang Huangqi decoction is effective for the treatment of type I and II MG and improves the associated clinical symptoms. Moreover, this agent is conducive to dose reductions and discontinuation of basic Western medicines, thereby reducing the side effects experienced by patients.
摘要：
探讨复方黄芪汤联合溴化吡啶斯的明片的临床疗效,泼尼松,通过对100例Ⅰ型和Ⅱ型重症肌无力(MG)患者临床症状评分的变化,探讨他克莫司治疗Ⅰ型和Ⅱ型重症肌无力(MG)的临床疗效。本研究还旨在研究这3种西药在服用复方黄芪汤后的剂量减少和不连续。
辽宁中医药大学附属医院门诊部100例Ⅰ、Ⅱ型MG患者的临床资料，中国,收集了2017年6月至2020年6月之间的数据。根据患者是否服用了溴化吡啶斯的明片分为4组,泼尼松,和/或他克莫司在医院就诊时：复方黄芪汤组（A组），溴吡啶斯的明片+复方黄芪汤组(B组),溴吡啶斯的明片+泼尼松+复方黄芪汤组(C组),溴吡啶斯的明片+他克莫司+复方黄芪汤组(D组)。平均治疗时间(15.6±11.5)个月(0.5～55个月)。分析4组患者用药及3种西药减量停药后临床症状评分的变化。
100例患者治疗后（15.6±11.5）个月（范围0.5-55个月），总有效率为86.00％。A组有效率为85.71%,B组88.24%,C组76.92%,D组80.00%,B组69.12%的患者在(4.2±4.1)个月后首次减量,B组45.59％的患者在（8.8±6.1）个月后停用溴吡啶斯的明。C组有46.15%的患者在（5.3±3.4）个月后首次使用溴吡啶斯的明，C组23.08%的患者在(19.8±11.0)个月后停用溴吡啶斯的明；76.92%在(2.8±1.9)个月后减少激素用量，23.08%在(6.7±2.9)个月后停止激素治疗。D组1例患者在1个月后减少了溴化吡啶斯的明的剂量；该患者在3个月后停止了溴化吡啶斯的明，并在5个月后减少了他克莫司的剂量。D组1例患者于0.5个月时主动停用溴化吡啶斯的明和他克莫司，服用复方黄芪汤2个月，未停用西药。
复方黄芪汤治疗Ⅰ、Ⅱ型MG有效，改善相关临床症状。此外，这种药物有利于减少剂量和停用基本的西药，从而减少患者所经历的副作用。
辽宁中医药大学附属医院门诊部100例Ⅰ、Ⅱ型MG患者的临床资料，中国,收集了2017年6月至2020年6月之间的数据。根据患者是否服用了溴化吡啶斯的明片分为4组,泼尼松,和/或他克莫司在医院就诊时：复方黄芪汤组（A组），溴吡啶斯的明片+复方黄芪汤组(B组),溴吡啶斯的明片+泼尼松+复方黄芪汤组(C组),溴吡啶斯的明片+他克莫司+复方黄芪汤组(D组)。平均治疗时间(15.6±11.5)个月(0.5～55个月)。分析4组患者用药及3种西药减量停药后临床症状评分的变化。
100例患者治疗后（15.6±11.5）个月（范围0.5-55个月），总有效率为86.00％。A组有效率为85.71%,B组88.24%,C组76.92%,D组80.00%,B组69.12%的患者在(4.2±4.1)个月后首次减量,B组45.59％的患者在（8.8±6.1）个月后停用溴吡啶斯的明。C组有46.15%的患者在（5.3±3.4）个月后首次使用溴吡啶斯的明，C组23.08%的患者在(19.8±11.0)个月后停用溴吡啶斯的明；76.92%在(2.8±1.9)个月后减少激素用量，23.08%在(6.7±2.9)个月后停止激素治疗。D组1例患者在1个月后减少了溴化吡啶斯的明的剂量；该患者在3个月后停止了溴化吡啶斯的明，并在5个月后减少了他克莫司的剂量。D组1例患者于0.5个月时主动停用溴化吡啶斯的明和他克莫司，服用复方黄芪汤2个月，未停用西药。
复方黄芪汤治疗Ⅰ、Ⅱ型MG有效，改善相关临床症状。此外，这种药物有利于减少剂量和停用基本的西药，从而减少患者所经历的副作用。
